In this episode of One Step Ahead, we focus on the role energy producers can and should play in the race to “Net Zero” emissions. The key date is 2050, enshrined in the Paris Agreement, which commits nearly 200 countries to contain global warming at a maximum of 1.5°C above pre-industrial levels. One company well on its way in the low carbon transition is Spanish electric utility Iberdrola. Isabel Sánchez Herrero, Head of Investor Relations at Iberdrola, explains why the company is already 20 years ahead of the curve, and reveals its plans to help secure our planet’s future. From increased investments in renewables, to smart grid development, to the exciting potential of green hydrogen, the opportunity set for companies and investors willing to make a difference looks promising.

This episode was presented by Libby Potter

See omnystudio.com/listener for privacy information.

In this episode of One Step Ahead, we take a deep dive on a key component of the future mobility value chain – electric batteries. With close to a quarter of global carbon emissions coming from the transport sector, phasing out internal combustion engines (ICE) in favour of electric vehicles (EV) will be essential in the race to Net Zero. Benoit Lemaignan, Co-founder and CEO of French battery maker Verkor, and Diego Pavia, CEO of EIT InnoEnergy, an EU-backed investor in sustainable energy projects, talk us through the challenges and opportunities of electrifying transport. They explain why a rapid scaling up of battery production is needed to meet the growing demand for EVs, how battery recycling contributes to the circular economy, and why the new mobility business segment could be up to seven times bigger over the next decade.

This episode was presented by Libby Potter

See omnystudio.com/listener for privacy information.

***As of 28 December 2021, Novo Nordisk completed its acquisition of Dicerna Pharmaceuticals. This episode was recorded prior to the acquisition on 26 August 2021.***

In this episode of One Step Ahead, Douglas Fambrough, Ph.D., President and CEO at Dicerna Pharmaceuticals, talks us through “RNA interference,” an innovative technique that can target and silence certain disease-causing genes. From kidney-related disease to neurological disorders – and potentially even alcohol use disorder – he asserts that gene-based medicines have the potential to be a safe and effective approach to treating disease. According to Dr. Fambrough, we’re at the early stages of a “big bang” for gene-based medicine, and RNAi is just one of many disruptive technologies set to change the future of healthcare.

This episode was presented by Libby Potter.

See omnystudio.com/listener for privacy information.